{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001678","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.220318+00:00","generated_at":"2026-06-08T08:38:49.567451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Charles River Q3 results beat; narrows and raises non-GAAP EPS guidance for 2023","bullets":["Q3 revenue $1.03B (+3.8% YoY); GAAP EPS $1.69 (-10.1%), non-GAAP EPS $2.72 (+3.4%).","Organic revenue growth 4.1%, driven by DSA (+5.3% organic) and RMS (+3.2% organic).","DSA segment GAAP operating margin down to 22.1% from 22.9%; non-GAAP up to 27.2% from 26.2%.","RMS GAAP op margin 15.2% vs 19.9% prior; Manufacturing op margin down on GAAP and non-GAAP basis.","FY2023 guidance: organic rev growth 5.5%-6.5% (narrowed from 5.5%-7.5%); non-GAAP EPS $10.50-$10.70 (prior $10.30-$10.90)."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001678","json":"https://secwatch.observer/filing/0001157523-23-001678.json","markdown":"https://secwatch.observer/filing/0001157523-23-001678.md","text":"https://secwatch.observer/filing/0001157523-23-001678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323001678/0001157523-23-001678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323001678/a53773748.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:38:49.567451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e880b83bb8f127698c8af0a543c0827e50981e1","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the third quarter of 2023 results: revenue $1.03 billion, net income $87.4 million, EPS $1.69. Guidance lowered.","evidence_excerpt":"EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a53773748ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2023 Results – Third-Quarter Revenue of $1.03 Billion – – Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 – – Updates 2023 Guidance – WILMINGTON, Mass.--(BUSINESS WIRE)--November 8,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323001678/0001157523-23-001678-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$1.03 billion"},{"label":"Net income","value":"$87.4 million"},{"label":"EPS","value":"$1.69"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}